Safety of high dose bedaquiline treatment in patients with extensively drug-resistant tuberculosis
Abstract
Extract Bedaquiline (Bdq) was authorised for the treatment of multidrug-resistant (MDR) tuberculosis (TB) in 2014 in Europe. It is part of the preferred BPaLM regimen (Bdq, pretomanid, linezolid (Lzd), moxifloxacin (Mfx)), of individualised MDR-TB treatment and new MDR-TB regimens recommended by the recently updated World Health Organization guidelines [1]. Most trials aiming to develop new regimens for drug-resistant TB include Bdq, making it the most important drug at present. Shareable abstract In XDR-TB cases with low-level bedaquiline resistance, higher bedaquiline dosing is discussed when other options are limited. This series of 5 cases provides the first safety data, supporting further research on individualised Bdq dosing for XDR-TB cases. https://bit.ly/4922qbI
Read the paper
Related studies
- Synthesis, In Vitro and In Silico Molecular Docking Studies of Novel Phthalimide–Pyrimidine Hybrid Analogues to Thalidomide as Potent Antitubercular Agents
- Exploring the inhibitory performance of expired moxifloxacin and norfloxacin on copper corrosion in saline environment
- Molecular investigation of antimicrobial peptides against Helicobacter pylori proteins using a peptide-protein docking approach
- Screening of novel narrow-spectrum benzofuroxan derivatives for the treatment of multidrug-resistant tuberculosis through in silico, in vitro, and in vivo approaches
- Synthesis, Characterization, Anticancer, Antioxidant, and In Silico Evaluation of Semicarbazides and Thiosemicarbazides
- Fast and accurate prediction of drug induced proarrhythmic risk with sex specific cardiac emulators
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.